Theranostics Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export 

Expanding Oncology Applications Driving Theranostics Market 

The theranostics market is witnessing significant momentum owing to the exponential rise in oncology applications. According to Datavagyanik, the increasing incidence of cancer is one of the strongest forces propelling the theranostics market. For instance, global cancer cases surpassed 19 million in 2022, and this figure is expected to reach 24 million by 2030, which has directly stimulated investments in targeted theranostic platforms. The theranostics market is experiencing breakthroughs such as radioligand therapies that enable targeted tumor visualization and treatment in a single procedure, offering far superior precision compared to conventional chemotherapy. For example, prostate-specific membrane antigen (PSMA) theranostic solutions have shown an average improvement of 35% in tumor targeting accuracy, boosting the overall attractiveness of the theranostics market. 

Rising Adoption of Personalized Medicine Fueling Theranostics Market 

The shift toward personalized medicine is creating new opportunities for the theranostics market. According to Datavagyanik, close to 80% of oncology trials are now using biomarker-driven strategies, which directly supports theranostic adoption. For instance, breast cancer biomarkers such as HER2 have driven demand for tailored theranostic approaches, achieving treatment response improvements of over 40% compared to non-targeted therapies. The theranostics market is therefore experiencing robust growth as healthcare providers increasingly deploy companion diagnostics together with therapeutics to improve patient outcomes. These strategies are expected to contribute to a CAGR of approximately 11% for the theranostics market through 2030, propelled by the expanding ecosystem of precision oncology solutions. 

Technological Innovations Reinforcing Theranostics Market Growth 

Continuous advancements in imaging and radiopharmaceuticals are catalyzing the expansion of the theranostics market. For instance, the integration of gallium-68 and lutetium-177–based radiopharmaceuticals has enabled far more effective tumor localization and therapy in neuroendocrine tumors, improving progression-free survival rates by over 50%. According to Datavagyanik, such innovations are accelerating adoption by hospitals and specialized cancer centers, creating sustainable demand in the theranostics market. As more cutting-edge radioisotopes and imaging modalities become clinically available, the theranostics market will likely benefit from enhanced accuracy, safety, and patient-specific outcomes, leading to a significant expansion of its market footprint. 

Increased Prevalence of Chronic Disorders Expanding Theranostics Market 

Beyond oncology, the theranostics market is gaining traction for chronic and metabolic disorders. For example, cardiovascular diseases affected nearly 550 million people globally in 2023, and theranostic platforms are being developed to deliver targeted interventions for atherosclerotic plaques. According to Datavagyanik, chronic inflammatory disorders are another segment where theranostic solutions are expected to reduce overall treatment costs by up to 25% through earlier and more accurate diagnoses combined with precision therapies. The growing burden of such diseases is encouraging healthcare systems to adopt integrated theranostic protocols, which is projected to enhance the theranostics market’s reach into non-oncological applications in the coming years. 

Strategic Collaborations Strengthening Theranostics Market 

Strategic partnerships among pharmaceutical firms, diagnostics developers, and academic research institutes are further consolidating the theranostics market. According to Datavagyanik, more than 40% of theranostic projects in clinical pipelines are supported by cross-industry collaborations. For instance, the partnership between leading radiopharmaceutical manufacturers and PET imaging technology companies has resulted in improved molecule delivery systems, shortening diagnosis-to-treatment times by 30% in some advanced cancer cases. These synergies not only boost technology transfer but also accelerate regulatory pathways, helping the theranostics market achieve quicker commercial deployment. Such collaborative frameworks will continue to define the competitive landscape and shape the next decade of theranostic solutions. 

Rising Government Investments Supporting Theranostics Market 

Governments across advanced economies are ramping up investments in the theranostics market to address the surging burden of complex diseases. According to Datavagyanik, public funding for nuclear medicine research has grown by more than 22% in the past five years, with a major portion earmarked for theranostic trials. For instance, European health authorities have invested substantially in radiopharmaceutical manufacturing facilities to support large-scale adoption of PSMA and neuroendocrine theranostics. These public-sector investments are providing a critical foundation for the theranostics market to scale, as well as ensuring equitable patient access to high-value precision therapies. It is anticipated that public-private partnerships will expand further, securing a robust growth trajectory for the theranostics market. 

Growing Awareness Boosting Theranostics Market 

Patient and clinician awareness of precision interventions is steadily improving, driving the theranostics market. According to Datavagyanik, nearly 60% of oncologists surveyed in 2024 indicated a strong preference for theranostic-based regimens over conventional systemic therapies. For example, patient advocacy groups are increasingly demanding personalized options, which has led to a 28% rise in clinical referrals for theranostic imaging since 2021. This growing acceptance is helping the theranostics market to establish a stronger foothold across both urban and rural healthcare networks, improving patient outcomes while reducing unnecessary exposure to broad-spectrum treatments. 

Regulatory Support Advancing Theranostics Market 

Progressive regulatory frameworks are paving the way for faster growth in the theranostics market. For instance, streamlined approval procedures for radioligand therapies in North America have cut average approval timelines by nearly 18 months, according to Datavagyanik. Such policy clarity is encouraging investments in theranostic trials and manufacturing capacity, which has doubled in some European regions between 2020 and 2024. The theranostics market benefits tremendously from these frameworks, as stakeholders can deploy innovative therapies with greater confidence, avoiding prolonged approval cycles that previously stalled market entry. 

Theranostics Market Size Expanding with Broader Indications 

The theranostics market size is growing consistently as the technology expands beyond oncology into neurology and infectious diseases. According to Datavagyanik, theranostic approaches for neurodegenerative conditions such as Alzheimer’s disease are showing promise by enabling early amyloid plaque identification and targeted delivery of beta-amyloid clearance agents. This area alone is expected to generate more than $1.2 billion in incremental revenue for the theranostics market size by 2030, supported by a projected 17% CAGR in Alzheimer’s disease–targeted therapeutics. Such developments indicate the theranostics market will continue to broaden its reach into multiple high-burden disease categories. 

High Cost of Conventional Therapies Supporting Theranostics Market 

The high cost of traditional oncology and chronic disease therapies is creating a compelling case for the theranostics market. According to Datavagyanik, certain chemotherapy regimens can cost upwards of $150,000 per patient annually, while theranostic interventions have demonstrated comparable or better outcomes with a 20–30% reduction in total treatment costs. For instance, PSMA-ligand–based prostate cancer therapies have cut hospitalization rates by over 25%, lowering both direct and indirect medical expenses. These cost efficiencies are encouraging payers and insurance systems to prioritize reimbursement for theranostic solutions, thereby fueling the theranostics market across developed and emerging economies alike. 

Rapid Diagnostics Adoption Elevating Theranostics Market 

Faster diagnostic timelines are reshaping the theranostics market by enabling same-day treatment strategies. According to Datavagyanik, over 45% of cancer centers have upgraded their nuclear imaging infrastructure between 2022 and 2024, allowing them to initiate theranostic-based therapies within hours of a confirmed diagnosis. For example, gallium-68–based PET scans provide immediate results for neuroendocrine tumors, accelerating treatment planning and improving survival rates by nearly 20% compared to standard diagnostic approaches. The theranostics market is therefore benefiting from significant efficiencies in clinical workflow, which translate to improved patient throughput and higher profitability for treatment centers. 

Theranostics Market Advancing with Emerging Biomarkers 

The discovery of novel biomarkers is further driving the theranostics market forward. According to Datavagyanik, nearly 500 new molecular targets are under investigation in clinical pipelines globally, expanding beyond traditional cancer biomarkers to include neuroinflammation and cardiac fibrosis indicators. For instance, fibroblast activation protein–targeted tracers are in phase II trials for various fibrotic disorders, potentially adding $900 million in market opportunity to the theranostics market by 2030. As this biomarker landscape evolves, developers will have new avenues to design more tailored, high-precision theranostic interventions, consolidating the theranostics market’s role in precision health. 

 

”Track Country-wise Theranostics Production and Demand through our Database”

• • • • Theranostics sales volume database for 27+ countries worldwide

 

North America Leading Theranostics Market with Robust Demand 

The theranostics market in North America is demonstrating remarkable growth, supported by advanced healthcare infrastructure and proactive investments. According to Datavagyanik, the United States accounts for nearly 42% of global theranostics revenues as of 2024, driven by high adoption rates in precision oncology and neuroendocrine tumor management. For instance, the country recorded over 100,000 PSMA-targeted procedures in prostate cancer patients in 2023, reflecting its leadership position in the theranostics market. Additionally, the presence of world-class research centers and a mature reimbursement framework ensures continuous market expansion, with projections indicating a CAGR exceeding 10% through 2030. The United States is also actively investing in next-generation theranostic radioisotopes, establishing a solid foundation for further growth in the regional theranostics market. 

Europe Expanding Theranostics Market Through Cross-Border Collaborations 

The European theranostics market is evolving rapidly due to well-coordinated public-private partnerships and cross-border research initiatives. According to Datavagyanik, countries such as Germany, France, and the United Kingdom have collectively invested more than $800 million since 2020 to expand theranostic infrastructure. For example, the rollout of centralized radiopharmaceutical distribution hubs across Western Europe has improved patient access and reduced therapy turnaround times by nearly 25%, strengthening the competitive positioning of the regional theranostics market. Moreover, regulatory harmonization across the EU has streamlined clinical approvals for theranostic compounds, encouraging manufacturers to increase their production capacity and drive deeper market penetration. 

Asia Pacific Theranostics Market Showing High Growth Potential 

The Asia Pacific theranostics market is expected to deliver the highest growth rates among all regions, supported by a large patient pool and an expanding healthcare ecosystem. According to Datavagyanik, countries like China, India, and South Korea are projected to achieve a CAGR of 14% through 2030. For example, China has witnessed a 35% annual rise in the number of nuclear medicine centers since 2021, enabling faster adoption of targeted radioligand therapies. Furthermore, government incentives to promote localized theranostics manufacturing are helping regional players reduce reliance on imports and strengthen self-sufficiency. This domestic production push is expected to significantly improve affordability and accessibility across the Asia Pacific theranostics market. 

Middle East and Africa Emerging in Theranostics Market Adoption 

Although at an earlier stage, the theranostics market in the Middle East and Africa is gaining momentum due to a rising cancer burden and targeted healthcare investments. According to Datavagyanik, the region has experienced a 20% year-on-year increase in demand for nuclear medicine procedures over the last three years. For example, Saudi Arabia and the UAE have prioritized theranostics infrastructure upgrades, establishing radiopharmacy labs to support local demand and minimize lead times. As a result, the Middle East theranostics market is expected to witness double-digit growth, supported by a growing number of skilled radiopharmacists and specialized oncology clinics. 

Regional Price Trends Reshaping Theranostics Market 

Pricing dynamics within the theranostics market vary substantially by region. According to Datavagyanik, North America typically sees higher procedure costs, averaging between $12,000 and $20,000 per cycle of PSMA theranostic treatment, due to advanced imaging standards and high reimbursement rates. In contrast, Europe maintains a moderate price point, averaging $9,000 per cycle, supported by centralized procurement systems that drive down costs. Meanwhile, Asia Pacific offers lower prices ranging from $5,000 to $7,000 per procedure, thanks to emerging local theranostics manufacturing and competitive service networks. These price trends will likely play a defining role in market adoption, with cost-competitive regions gaining share over time. 

Theranostics Manufacturing Expanding to Meet Rising Demand 

Theranostics manufacturing is scaling rapidly to keep pace with surging demand. According to Datavagyanik, global capacity for radiopharmaceutical production has increased by 28% between 2021 and 2024. For instance, new cyclotron installations across Europe and Asia have allowed manufacturers to produce gallium-68 and lutetium-177 isotopes on a larger scale, reducing bottlenecks in theranostics market supply chains. Theranostics manufacturing is also evolving to incorporate more sustainable production methods, such as lower-energy cyclotrons and automated purification systems, cutting operating costs by 15% on average. As demand continues to rise, these innovations will support consistent growth across the global theranostics market. 

Contract Manufacturing Fueling Theranostics Market Scalability 

Contract-based theranostics manufacturing is becoming a preferred model, especially among emerging biotech players lacking in-house capabilities. According to Datavagyanik, contract manufacturing organizations have captured nearly 38% of theranostic production capacity worldwide as of 2024. For example, contract manufacturing of PSMA ligands has allowed smaller firms to commercialize novel therapies without heavy capital expenditures. This model supports faster time-to-market, flexibility in production volumes, and easier compliance with region-specific regulations, thereby promoting robust scalability for the theranostics market. As more specialized contract manufacturers emerge, this trend is expected to further streamline access to customized radiopharmaceuticals. 

Raw Material Availability Supporting Theranostics Manufacturing 

Reliable raw material sourcing is essential for a stable theranostics market. According to Datavagyanik, demand for enriched stable isotopes such as ytterbium-176 and germanium-68 has increased by more than 40% since 2020, prompting suppliers to expand mining and enrichment capacities. For example, a new enrichment facility commissioned in South Korea has boosted annual gallium-68 output by 25%, stabilizing prices for key precursors in theranostics manufacturing. These efforts are critical to avoid shortages, maintain predictable lead times, and ensure consistent availability of radiopharmaceutical agents. As demand keeps growing, further investment in upstream raw material capacity will be crucial for maintaining momentum in the theranostics market. 

Segmentation of Theranostics Market by Application Areas 

Segmentation of the theranostics market by application areas reveals a dominant share for oncology, which accounted for over 70% of total revenues in 2024 according to Datavagyanik. Within oncology, prostate cancer and neuroendocrine tumors are the largest contributors, thanks to well-established radioligand protocols that improve patient outcomes by up to 45% over traditional methods. Cardiovascular applications represent another fast-growing segment, with pilot theranostic interventions reducing post-infarction scarring by approximately 30% in early studies. Meanwhile, neurodegenerative disorders such as Alzheimer’s disease are projected to increase their share of the theranostics market from 4% to 9% by 2030, fueled by the development of amyloid-targeted theranostic compounds. 

Segmentation of Theranostics Market by Radiopharmaceutical Type 

Analyzing the theranostics market by radiopharmaceutical type, lutetium-177–based agents hold the largest share, followed by iodine-131 and actinium-225–based solutions. According to Datavagyanik, lutetium-177 has been preferred for its favorable half-life and high tumor affinity, capturing nearly 52% of market volume in 2024. For example, lutetium-177–PSMA therapy has shown tumor shrinkage rates exceeding 60% in advanced prostate cancer patients, encouraging its adoption worldwide. Emerging isotopes such as terbium-161 are also gaining interest for their high linear energy transfer, with early-phase trials suggesting superior results in small-volume tumor control. This evolving radiopharmaceutical landscape will continue to influence market segmentation and stimulate competitive differentiation within the theranostics market. 

Theranostics Manufacturing Automation Optimizing Production 

Automation is transforming theranostics manufacturing by improving yield, safety, and regulatory compliance. According to Datavagyanik, automated synthesis modules have cut human error rates by 40% while improving batch reproducibility, making them highly attractive to radiopharmaceutical producers. For instance, automated cassette-based synthesis has reduced production turnaround times from 4 hours to just 2 hours in certain gallium-68–based compounds, significantly increasing output capacity. This efficiency supports the growing theranostics market by providing reliable, high-quality radiopharmaceuticals that meet the strict regulatory requirements of global health authorities. 

Price Trend Dynamics in Theranostics Market 

Price dynamics in the theranostics market are subject to evolving cost structures and market consolidation. According to Datavagyanik, the average cost of a complete theranostic cycle is expected to decline by 12% by 2028, driven by economies of scale and greater automation in theranostics manufacturing. For example, centralized isotope production facilities have already reduced per-unit costs of gallium-68 precursors by 18% between 2021 and 2024. However, high R&D spending for next-generation radiopharmaceuticals may offset some of these cost benefits, maintaining premium pricing in the short term. These mixed price movements will likely define the competitiveness and affordability of the theranostics market through the remainder of the decade. 

Regional Expansion of Theranostics Manufacturing 

Regional theranostics manufacturing hubs are emerging as governments push for local supply security. According to Datavagyanik, Asia Pacific alone has added over 15 new radiopharmaceutical production facilities since 2022, supporting cost-effective and timely delivery of critical agents. For instance, India’s initiatives to localize gallium-68 manufacturing have reduced import dependence by 40%, while maintaining stringent safety standards. Such regional manufacturing growth not only boosts supply chain resilience but also ensures fair pricing, which is crucial for sustaining the rapid adoption of theranostic solutions across diverse populations in the global theranostics market. 

Theranostics Market Segmentation by End Users 

End-user segmentation within the theranostics market highlights hospitals and cancer centers as the dominant customers, accounting for nearly 65% of all procedures in 2024. According to Datavagyanik, these institutions have invested heavily in theranostic infrastructure, including PET/CT scanners, radiopharmacy clean rooms, and specialized staff training. Specialty clinics and outpatient facilities represent an emerging end-user segment, with their share expected to rise from 12% to 19% by 2030 due to their ability to deliver high-volume, lower-cost theranostic interventions. This diversified end-user base will help broaden the reach of the theranostics market while optimizing treatment accessibility for patients worldwide. 

Theranostics Market Set for Disruptive Growth Through Innovation 

The theranostics market is expected to undergo transformative growth as new innovations reshape clinical practice. According to Datavagyanik, breakthroughs in alpha-emitting isotopes and dual-modality imaging could expand the market by an additional $5 billion by 2030. For example, alpha-emitters like actinium-225 have demonstrated tumor-killing abilities up to 100 times higher than beta-emitters, presenting significant opportunities to treat resistant cancers. As more innovation enters the market, manufacturing, pricing, and regional dynamics will continue to adapt, positioning the theranostics market as a cornerstone of the future precision medicine landscape. 

 

“Theranostics Manufacturing Database”

• • • Theranostics top manufacturers market share for 27+ manufacturers
    • Top 7 manufacturers and top 17 manufacturers of Theranostics in North America, Europe, Asia Pacific
    • Theranostics sales dashboard, Theranostics sales data in excel format

 

Top Manufacturers Shaping the Theranostics Market Landscape 

The theranostics market is highly competitive and features a group of leading manufacturers with robust product pipelines and diversified portfolios. Among the top players are GE HealthCare Technologies, Bayer AG, Advanced Accelerator Applications (AAA), Cardinal Health, Curium Pharma, Telix Pharmaceuticals, Lantheus Medical Imaging, and China Grand Pharmaceutical & Healthcare. Together, these companies account for over 60% of the global theranostics market share by combining radiopharmaceutical innovation with sophisticated delivery and imaging infrastructure. Their ability to provide fully integrated solutions from isotope production to therapeutic application gives them a powerful competitive edge and shapes the direction of the global theranostics market. 

GE HealthCare’s Dominance in Theranostics Market 

GE HealthCare has established itself as a leading name in the theranostics market thanks to a portfolio that blends radiopharmaceutical production systems with advanced molecular imaging. Its Discovery IQ PET/CT scanner series, for example, enables seamless imaging in combination with theranostic radioisotopes, while its cyclotron systems allow on-site isotope production, reducing lead times for therapy delivery. GE’s market share is estimated around 15 to 18%, supported by a growing installed base of integrated radiopharmacy solutions. By empowering hospitals and cancer centers to scale their theranostic services, GE HealthCare continues to hold a central place in the global theranostics market. 

Bayer and Advanced Accelerator Applications Anchoring Theranostics 

Bayer, through its Advanced Accelerator Applications subsidiary, is a significant contributor to the theranostics market, holding a market share between 12 and 14%. Its flagship product Lutathera, a lutetium-177–based treatment for neuroendocrine tumors, remains a dominant therapy worldwide, with consistently high clinical response rates. In addition, Bayer’s Axumin product line, based on fluciclovine F-18, supports prostate cancer imaging across a large network of nuclear medicine centers. These solutions have delivered tangible survival improvements and streamlined treatment pathways, strengthening Bayer’s foothold and reinforcing the theranostics market’s steady expansion. 

Cardinal Health Expanding Theranostics Manufacturing Reach 

Cardinal Health plays a vital role in theranostics manufacturing and distribution, providing hospitals and clinics with reliable, standardized radiopharmaceutical delivery. Its customized systems, including AmbryDose and PreciseDose platforms, enable safe and efficient handling of gallium-68 and lutetium-177 doses. Cardinal Health maintains approximately 8 to 10% market share, supported by an expanding network of radiopharmacies and growing capabilities in radioisotope supply chains. The firm’s strategy of integrating logistics, regulatory compliance, and production capacity is setting a benchmark for scalable, high-quality theranostics manufacturing in the market. 

Curium Pharma and Lantheus Building Regional Theranostics Market Strength 

Curium Pharma has established itself as a trusted supplier of gallium-68–based solutions for neuroendocrine tumors, capturing roughly 7 to 9% of the global theranostics market share. With multiple European radiopharmaceutical plants and regional distribution hubs, Curium ensures consistent, cost-effective access to theranostic agents. Similarly, Lantheus Medical Imaging holds a comparable share, supported by its highly specialized PYLARIFY product line for prostate cancer imaging, which has been rolled out to over 100 hospitals in North America. These manufacturers continue to shape regional theranostics adoption through localized production and strong clinical partnerships. 

Telix Pharmaceuticals Emerging as a Theranostics Market Innovator 

Telix Pharmaceuticals is a rising force in the theranostics market, with a portfolio targeting prostate and kidney cancers. Its PSMA-focused imaging and therapeutic products, including TLX591-CDx and TLX592, have advanced into later-stage clinical trials, showing promising response rates in resistant disease profiles. Telix currently holds an estimated 4 to 6% share of the theranostics market but is on track for rapid growth thanks to its strategy of expanding into fibroblast activation protein–targeted candidates. This clinical pipeline diversification strengthens its future positioning and supports ongoing innovation across the broader theranostics market. 

China Grand Pharmaceutical Advancing Regional Theranostics 

China Grand Pharmaceutical & Healthcare is leveraging regional supply chains to grow its theranostics manufacturing base, capturing around 5 to 7% of the global market. Its gallium-68 and iodine-131 production units in mainland China serve over 50 local nuclear medicine centers, reducing import dependence and stabilizing product pricing. By investing in modern radiopharmacy infrastructure and workforce training, China Grand is not only improving local access but also elevating the regional profile of the theranostics market. 

Theranostics Market Share by Manufacturer: A Competitive Picture 

The global theranostics market exhibits a high degree of concentration among its largest manufacturers, who together account for a major share of revenues and product volumes. GE HealthCare, Bayer/AAA, and Cardinal Health collectively represent nearly 40% of market share, while regional players including Curium, Lantheus, Telix, and China Grand fill in the next tier. Smaller specialized developers and contract manufacturing partners collectively hold about 20% of the market, often focusing on niche isotopes or emerging biomarkers. This segmentation highlights how the theranostics market rewards companies with deep vertical integration, well-developed clinical relationships, and the technical capacity to produce highly regulated radiopharmaceuticals at scale. 

Recent Industry Developments and Strategic Moves 

In the first quarter of 2025, Telix Pharmaceuticals completed a strategic acquisition of fibroblast activation protein–targeted compounds, strengthening its oncology-focused clinical pipeline and creating new treatment options for solid tumors. 

In March 2025, GE HealthCare launched an upgraded AI-enabled PET/CT platform specifically designed for theranostic imaging, supporting same-day diagnosis and targeted therapy planning for prostate cancer and neuroendocrine tumors. 

In June 2025, new collaborations between Integrated Theranostics Solutions and regional clinics in North America resulted in a turnkey theranostic therapy program, designed to reduce therapy wait times and expand access to radioligand-based treatment pathways. 

At the close of 2024, Bayer announced new production capacity expansions for its Lutathera line in Europe, aiming to meet growing demand for neuroendocrine tumor treatment projected to increase by 15% annually through 2030. 

China Grand Pharmaceutical, meanwhile, reported in early 2025 that its latest gallium-68 manufacturing site achieved commercial readiness, a step expected to reduce average supply lead times by 30% for hospitals in eastern China. 

The ongoing emphasis on precision health, robust product pipelines, and investment in theranostics manufacturing capacity all suggest that the theranostics market is set for continued, dynamic growth in the next decade. With manufacturers strengthening their capabilities and building regional supply chains, the industry is on a clear path to transforming cancer and chronic disease management for millions of patients worldwide. 

 

“Theranostics Production Data and Theranostics Production Trend”

• • • Theranostics sales database for historical years, 10 years historical data
    • Theranostics sales data and forecast for next 7 years

Key Insights that the Theranostics Market analysis report presents are:

• Theranostics Market revenue and demand by countries
• Break-down of the Theranostics Market in terms of application areas, target customers, and other potential market segments
• Areas that are relatively more potential and are faster growing
• Theranostics Market competitive scenario, market share analysis
• Theranostics Market business opportunity analysis

Global and Country-Wise Theranostics Market Statistics

• Global and Country-Wise Theranostics Market Size ($Million) and Forecast, till 2030
• Global and Country-Wise Theranostics Market Trend Analysis
• Global and Country-Wise Theranostics Market Business Opportunity Assessment